Furthermore, Endo-Munoz et al. [90] demonstrated that elevation of the urokinase plasminogen activator (uPA) and the uPA receptor (uPAR) in both soluble form and osteosarcoma-secreted EVs were exclusive in metastatic osteosarcoma cells, where the uPA inhibitor significantly mitigated osteosarcoma metastasis in an orthotopic mouse model [90]. The gene discussed is PLAU; the disease is osteosarcoma.